GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Durata Therapeutics Inc (FRA:DTA) » Definitions » Asset Turnover

Durata Therapeutics (FRA:DTA) Asset Turnover : 0.13 (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is Durata Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Durata Therapeutics's Revenue for the three months ended in Sep. 2014 was €7.82 Mil. Durata Therapeutics's Total Assets for the quarter that ended in Sep. 2014 was €61.10 Mil. Therefore, Durata Therapeutics's Asset Turnover for the quarter that ended in Sep. 2014 was 0.13.

Asset Turnover is linked to ROE % through Du Pont Formula. Durata Therapeutics's annualized ROE % for the quarter that ended in Sep. 2014 was 1,191.29%. It is also linked to ROA % through Du Pont Formula. Durata Therapeutics's annualized ROA % for the quarter that ended in Sep. 2014 was -102.07%.


Durata Therapeutics Asset Turnover Historical Data

The historical data trend for Durata Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durata Therapeutics Asset Turnover Chart

Durata Therapeutics Annual Data
Trend Dec11 Dec12 Dec13
Asset Turnover
- - -

Durata Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.13

Competitive Comparison of Durata Therapeutics's Asset Turnover

For the Biotechnology subindustry, Durata Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Durata Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Durata Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Durata Therapeutics's Asset Turnover falls into.



Durata Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Durata Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2013 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2013 )/( (Total Assets (A: Dec. 2012 )+Total Assets (A: Dec. 2013 ))/ count )
=0/( (65.95+73.105)/ 2 )
=0/69.5275
=0.00

Durata Therapeutics's Asset Turnover for the quarter that ended in Sep. 2014 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2014 )/( (Total Assets (Q: Jun. 2014 )+Total Assets (Q: Sep. 2014 ))/ count )
=7.823/( (58.47+63.727)/ 2 )
=7.823/61.0985
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Durata Therapeutics  (FRA:DTA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Durata Therapeutics's annulized ROE % for the quarter that ended in Sep. 2014 is

ROE %**(Q: Sep. 2014 )
=Net Income/Total Stockholders Equity
=-62.364/-5.235
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-62.364 / 31.292)*(31.292 / 61.0985)*(61.0985/ -5.235)
=Net Margin %*Asset Turnover*Equity Multiplier
=-199.3 %*0.5122*-11.6712
=ROA %*Equity Multiplier
=-102.07 %*-11.6712
=1,191.29 %

Note: The Net Income data used here is four times the quarterly (Sep. 2014) net income data. The Revenue data used here is four times the quarterly (Sep. 2014) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Durata Therapeutics's annulized ROA % for the quarter that ended in Sep. 2014 is

ROA %(Q: Sep. 2014 )
=Net Income/Total Assets
=-62.364/61.0985
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-62.364 / 31.292)*(31.292 / 61.0985)
=Net Margin %*Asset Turnover
=-199.3 %*0.5122
=-102.07 %

Note: The Net Income data used here is four times the quarterly (Sep. 2014) net income data. The Revenue data used here is four times the quarterly (Sep. 2014) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Durata Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Durata Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Durata Therapeutics (FRA:DTA) Business Description

Traded in Other Exchanges
N/A
Address
Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.

Durata Therapeutics (FRA:DTA) Headlines

No Headlines